Skip to main content Skip to main navigation menu Skip to site footer

Mesenchymal stem cell (MSC) as a potential cell therapy for immune related disease


Mesenchymal Stem Cell (MSC) is a type of stem cell that not only has the ability to differentiate into several different lineages, but also has an immunomodulator activity. MSC modulte immune system by secreting several different cytokines those act synergistically like IL6, IL-10, TGFβ, PGE2, and HLA-G which inhibit T-cell differentiation and maturation of macrophage. Because of its immunomodulatory properties, several researches had attempted to study its potential application in autoimmune management. So far, preclinical and clinical study in Graft versus Host Disease (GVHD) and several autoimmune diseases like Systemic Lupus Erythematosus (SLE), and diabetes had yield promising results. However, the efficacy of its application in Inflammatory Bowel Disease (IBD) is still unclear. Overall, MSC has shown great promise as novel modality in autoimmune management. However, further studies are still needed to evaluate its application in each autoimmune disease as well as determining the effective dose of MSC for each type of autoimmune disease.


  1. Agarwal, S., & Pittenger, M.F. (2005). Human Mesenchymal Stem cell Modulate Alligenic Immune Cell responses. Blood 105, 1815-1822.
  2. Anna, M.W. 2008. Stem Cells. Springer, 248978-3-54077-854-7.
  3. Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., Moseley, A., &Hoffman, R. (2002). Mesenchymal Stem Cells Suppress Lymphocyte Proliferation In Vitro And Prolong Skin Graft Survival In Vivo. Exp Hematol 30(1): 42-8.
  4. Connick, P., Kolappan, M., Patani, R., Scott, M.A., Crawley, C., Xiao-Ling, H.E., Richardson, K., Barber, K., Webber, D.J., Tozer, C., Samson, R.S., Thomas, D.L., Du, M., Luan, S.L., Michell, A.W., Altmann, D.R., Thompson, A.J., Miller, D.H., Compston, A., & Chandran, S. (2011). The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials 12: 62
  5. Corcione, A., Benvenuto, F., & Ferretti, E. (2006). Human Mesenchymal Stem cell Modulate B-Cell Function. Blood 107, 367-372
  6. Dilal, J., Gandy, K., & Domen, J. (2012). Role of Mesenchymal Stem cell Therapy in Crohn’s Disease. Pediatric Research 71, 445-451
  7. Fiorina, P., Jeruwicz, M., Augello, A., Vergani, A., Dada, S., Rosa, S., Selig, M., Godwin, J., Law, K., Placidi, C., Smith, R.N., Capella, C., Rodig, S., Adra, C.N., Atkinson, M., Sayegh, M.H., & Abdi, R. (2009). Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cell in Experimental Autoimmune Type 1 Diabetes. The Journal of Immunology 183(2), 993-1004
  8. Gawlitta, D. 2013. Taking Mesenchymal Stem Cell From Bench to Bedside. In: Abstract book of the Stem Cell and Tissue Engineering Symposium and Workshop, (pp.76-77).Surabaya: Airlangga University.
  9. Halim, D., Murti, H., Sandra, F., Boediono, A., Djuwantono, T., and Setiawan, B. (Ed.). (2010). Stem Cell : Dasar Teori dan Aplikasi Klinis. Jakarta : Penerbit Erlangga.
  10. Jaiswal, R.K., Jaiswal, N., Bruder, S.P., Mbalaviele, G., Marshak, D.R., &Mark, F. P. (2000). Adult Human Mesenchymal Stem Cell Differentiation to the Osteogenic or Adipogenic Lineage is Regulated by Mitogen Activated Protein Kinase. J.Biol.Chem 275, 9645-9652.
  11. Jiang, X.X., Zhang, Y., & Liu, B. (2005). Human Mesenchymal Stem Cell Inhibit Differentiation and Function of Monocyte-Derived Dendritic Cells. Blood 105, 4120-4126
  12. Joo, S.Y., Cho, K.A., Jung, Y.J., Kim, H.S., Park, S.Y., Choi, Y.B., Hong, K.M., Woo, S.Y., Seoh, J.Y., Cho, S.J., &Ryu, K.H. (2010). Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy 12(3), 361-370
  13. Kern, S., Eichler, H., Stoeve, J., Kluter, H., & Bieback, K. (2006). Comparative Analysis of Mesenchymal Stem Cell from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue. Stem Cells 24, 1294-1301.
  14. Lim, H. (2nd Ed.). (2012). Stem Cell Kardiovaskuler. Jakarta : PT.Softmedia.
  15. Nauta, A.J., & Fibbe, W.E. (2007). Immunomodulatory Properties of Mesenchymal Stromal Cells. Blood110 (10), 3499-3506
  16. Purwati., Ferdiansyah., & Soeroso, J. (2013). Autologus Multipotent Mesenchymal Stem Cell in Patient with Ankylosing Spondylitis. In: Abstract book of the Stem Cell and Tissue Engineering Symposium and Workshop, (pp.18).Surabaya: Airlangga University.
  17. Rantam, F.A., Purwati, & Ferdiansyah. (2013). Biology, Isolation and Differentiation of Stem Cell. In: Abstract book of the Stem Cell and Tissue Engineering Symposium and Workshop, (pp.55-73).Surabaya: Airlangga University.
  18. Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., Marschall, H.U., Dlugosz, A., Szakos, A., Hassan, Z., Omazic, B., Aschan, J., Barkholt, L., &Le Blanc, K. (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(10),1390-1397.
  19. Rowland, T. J. (Ed.). (2009). Biology Bytes: Digestible Essays on Stem Cells and Modern Medicine. USA: Santa Barbara Independent, Inc.
  20. Salem, H.K., & Thiemermann, C. (2010). Mesenchymal Stromal Cell: current understanding and clinical status. Stem cell 28I, 585-596.
  21. Sotiropoulou, P.A., Perez, S.A., & Gritzapis, A.D. (2006). Interaction between Human Mesenchymal Stem cell and Natural Killer cell. Stem Cell 24, 74-85
  22. Sun, L., Akiyama, K., Zhang, H., Yamaza, T., Hou, Y., Zhao, S., Xu, T., Le, A., & Shi, S. (2009). Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and Human. Stem Cell 27, 1421-1432.
  23. Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., &Jones, J.M. (1998). Embryonic Stem Cell Lines Derived From Human Blastocyst. Science282, 1145-1147.
  24. Trivedi, H.L., & Vanikar, A.V. (2013). Mesenchymal Stem Cell and Solid Organ Transplantation. CellR4, 1(2), 123-136.
  25. Tse, W.T., Pendleton, J.D., & Beyer, W.M.. (2003). Suppression of Allogenic T-cell Proliferation by Human Marrow Stromal Cell: Implication in Transplantation. Transplantation, 75, 389-397.
  26. Van, P.P. (2011). Stem Cell Therapy for Islet Regeneration, Stem Cells in Clinic and Research, Dr. Ali Gholamrezanezhad (Ed.), ISBN: 978-953-307-797-0, InTech, DOI: 10.5772/17588. Retrieved August 27, 2014 from
  27. Yu, J., Zheng, C., Ren. X., Li, J., Liu, M., Zhang, L., Liang, L., Du, W, &Han, Z.C. (2010). Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action. ScandinavianJournal ofImmunology, 72(3), 242-249.

How to Cite

Hadi Kartiko, B., Milas Siswanto, F., & Purwata, T. E. (2017). Mesenchymal stem cell (MSC) as a potential cell therapy for immune related disease. Bali Medical Journal, 6(1), 38–43.




Search Panel

Bambang Hadi Kartiko
Google Scholar
BMJ Journal

Ferbian Milas Siswanto
Google Scholar
BMJ Journal

Thomas Eko Purwata
Google Scholar
BMJ Journal